Abstract. The vasculotropic E22Q mutant of the amyloid-b (Ab) peptide is associated with hereditary cerebral hemorrhage with amyloidosis Dutch type. The cellular mechanism(s) of toxicity and nature of the AbE22Q toxic assemblies are not completely understood. Comparative assessment of structural parameters and cell death mechanisms elicited in primary human cerebral endothelial cells by AbE22Q and wild-type Ab revealed that only AbE22Q triggered the Bax mitochondrial pathway of apoptosis. AbE22Q neither matched the fast oligomerization kinetics of Ab42 nor reached its predominant b-sheet structure, achieving a modest degree of oligomerization with a secondary structure that remained a mixture of b and random conformations. The endogenous molecule tauroursodeoxycholic acid (TUDCA) was a strong modulator of AbE22Q-triggered apoptosis but did not significantly change the secondary structures and fibrillogenic propensities of Ab peptides. These data dissociate the pro-apoptotic properties of Ab peptides from their distinct mechanisms of aggregation/fibrillization in vitro, providing new perspectives for modulation of amyloid toxicity.
Introduction
Cerebral amyloid angiopathy (CAA), a common feature of Alzheimers disease (AD), is an ageassociated condition characterized by the deposition of amyloid peptides in cortical and leptomeningeal vessels, causing capillary disruption and endothelium dysfunction and playing a significant role in intracerebral hemorrhage [1 -3] . Different proteins are associated with CAA (reviewed in [4, 5] ). The most common is amyloid-b (Ab), which is the main component of the deposits seen in normal aging and sporadic AD that originates by processing of the amyloid precursor protein (APP) (reviewed in [6] ). Of the several mutations identified in the APP gene, substitutions at residues flanking the Ab region affect the rate of enzymatic APP processing and the production of Ab42, resulting in an early-onset AD phenotype [7] . On the contrary, mutations within the Ab sequence, particularly at residues 21 -23, generate Ab variants Dutch, Iowa, Flemish, Artic and Italian [8 -11] , which preferentially associate with CAA, hemorrhagic strokes and/or dementia. One of the most aggressive clinical phenotypes described in familial AD is associated with a glutamine to glutamic acid substitution at residue 22 (E22Q), found in a disorder known as hereditary cerebral hemorrhage with amyloidosis Dutch type (HCHWA-D) [8] . The disease is characterized by recurrent strokes and vascular dementia in the absence of neurofibrillar pathology, with fatal cerebral bleeding resulting from the massive amyloid deposition in leptomeningeal vessels and cortical arteries and arterioles (reviewed in [12] ). Parenchymal mature plaques characteristic of AD are rare in this kindred, while diffuse preamyloid deposits are relatively frequent and show a remarkable relationship with age. They are more abundant in younger patients, suggesting that these lesions may develop into the less profuse mature fibrillar counterparts [13 -15] . In general, Ab mutants have been demonstrated to exert stronger toxicity than the wild-type counterparts in both neuronal [16] and cerebrovascular cells [9,17 -19] , although striking differences exist among the variants themselves. Differences in toxicity likely correlate with distinct structural properties conferred by the amino acid substitutions, which typically translate into enhanced fibrillogenic properties [20, 21] . These, in turn, influence the onset and aggressiveness of the respective clinical phenotypes (reviewed in [6] ). One of the most-studied mutants is the aggressive intra-Ab genetic variant E22Q. Following intraventricular injection in rats, this variant dramatically disrupts synaptic plasticity. Together with the Arctic (E22G) mutant, it is 100-fold more potent than wildtype Ab40 at inhibiting long-term potentiation [22] . The Dutch Ab peptide has also been shown to exert potent effects on vessel wall cells, exhibiting antiangiogenic properties [23] and inducing apoptosis in cerebral endothelial and smooth muscle cells, under conditions in which wild-type Ab had no effects [9, 17 -19] . Nevertheless, the cellular mechanism(s) by which Ab mutants induce toxicity remains poorly understood and requires further investigation. Tauroursodeoxycholic acid (TUDCA) is an endogenous bile acid known to play a key role in modulating the apoptotic threshold in various cell types by interfering with classical mitochondrial pathways of cell death [24] . Its antiapoptotic effects have been demonstrated in several pathological conditions, including different neurological disorders [25 -29] . TUDCA modulates Ab-induced cell death by inhibiting the mitochondrial pathway of apoptosis and enhancing survival signaling in rat cortical neurons [30] . Moreover, it can interfere with targets upstream of mitochondria, including cell cycle-related proteins E2F-1 and p53 [31] , through functional modulation of nuclear steroid receptors [32] . These data strongly suggest that TUDCA may also be beneficial in reducing other manifestations of brain amyloid toxicity, such as CAA. Many studies have been devoted to elucidate the mechanisms of Ab neurotoxicity. However, there is limited information available regarding the effect(s) of amyloid peptides on endothelial vessel wall cells that are in immediate contact with the vascular amyloid deposits in CAA. In this study, we compared aggregation/fibrillization properties, secondary structure, and cell death pathways of the Dutch variant and wild-type Ab40 and Ab42, both in the presence and absence of TUDCA. Our data dissociate the apoptotic properties of Ab peptides in human cerebral endothelial cells and their distinct mechanisms of aggregation in vitro, while providing new perspectives for modulation of amyloid-induced apoptosis.
Materials and methods
Peptide synthesis. Synthetic wild-type Ab40 and Ab42 peptides as well as Ab40 peptide containing the E22Q substitution were synthesized by James I. Elliott at Yale University using N-tert-butyloxycarbonyl chemistry and then purified by reverse phase-high performance liquid chromatography on a Vydac C4 column (Western Analytical, Murrieta, CA) [9, 33] . Molecular masses were corroborated by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry, and concentration assessed by amino acid analysis. All peptides were supplied as single components eluted from the reverse-phase columns with experimental molecular masses of 4329. 41 Peptide aggregation. Synthetic Ab homologues were dissolved to 1 mM in hexafluoro-isopropanol (HFIP; Sigma Chemical Co., St. Louis, MO), a pre-treatment that breaks down b-sheet structures and disrupts hydrophobic forces leading to monodisperse Ab preparations [34] . Following lyophilization to remove HFIP, peptides were subsequently solubilized in deionized water and added to an equal volume of a 2 concentrated phosphate-buffered saline (PBS), pH 7.4, to a final concentration of 1 mg/ml in 1 PBS. Peptides, in the presence or absence of 100 mM TUDCA (Sigma), were either incubated at 37 o C for up to 48 h for the aggregation studies or diluted into culture media at the required concentration for the toxicity experiments. For the aggregation studies, structural properties were assessed by Western blot analysis, circular dichroism (CD) spectroscopy and Thioflavin T binding.
Peptide structural analysis. For the Western blot analysis, 200 ng aliquots of each peptide either freshly solubilized or after 24 and 48 h of aggregation, in the presence or absence of TUDCA, were separated on 16.5 % Tris-Tricine SDS-polyacrylamide gel electrophoresis (PAGE). After electrophoresis, proteins were electrotransferred to nitrocellulose membranes (Hybond-ECL; GE Healthcare Life Sciences, Piscataway, NJ) using 10 mM 3-cyclohexylamino-1-propanesulfonic acid (Sigma) buffer, pH 11.0, containing 10 % (v/v) methanol, at 400 mA for 2 h. After blocking in 5 % nonfat milk in PBS containing 0.1 % Tween 20, the membranes were immunoreacted with a combination of mouse monoclonal anti-Ab antibodies 4G8 (epitope: residues Ab18 -22) and 6E10 (epitope: residues Ab3 -8), both from Covance (Princeton, NJ), at a 1/3000 dilution each, followed by incubation with horseradish peroxidase (HRP)-labeled F(ab')2 antimouse IgG (1/5000; GE Healthcare Life Sciences). Fluorograms were developed with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL) and exposed to Hyperfilm ECL (GE Healthcare Life Sciences). The secondary structure of Ab peptides was estimated by CD spectroscopy as previously described [9, 33] . Spectra in the far-UV light (190 -260 nm; bandwidth, 1 nm; intervals, 1 nm; scan rate, 60 nm/min) yielded by the different peptides at each time point of aggregation were recorded at 24 C with a Jasco J-720 spectropolarimeter (Jasco Corp., Tokyo, Japan), using a 0.2-mm-path quartz cell and a peptide concentration of 1 mg/ml. For each sample, 15 consecutive spectra were obtained, averaged and baseline-subtracted. Results were expressed in terms of mean residue ellipticity (degree-cm 2 dmol -1
) [35] . Thioflavin T binding was assessed essentially as previously described [36, 37] . Six-microliter aliquots of each of the peptide aggregation time-point samples were added to 10 ml of 0.1 mM Thioflavin T (Sigma) and 50 mM Tris-HCl buffer, pH 8.5 to a final volume of 200 ml. Fluorescence was recorded after 300 s in a LS-50B luminescence spectrometer (Perkin Elmer, Waltham, MA) with excitation and emission wavelengths of 435 nm (slit width=10 nm) and 490 nm (slit width=10 nm), respectively. Each sample was analyzed in duplicate.
Culture of human brain microvascular endothelial cells. Primary human cerebral endothelial cells (HCEC; Cell Systems, Kirkland, WA) were grown in CS-C Complete Medium on dishes coated with Attachment Factor (Cell Systems), at 378C in a 5% CO 2 atmosphere. For cell death assays and immunocytochemistry, cells were plated at a density of 410 4 cells/ml. For immunoblotting, cells were plated at a density of 110 5 cells/ml. In all cases, cells were allowed to rest for 1 day prior to treatment with the Ab peptides.
Induction of apoptosis. HFIP pre-treated Ab peptides were dissolved to 500 mM in PBS, as indicated above, and subsequently added to warm F12K Nutrient Mixture (Invitrogen/Gibco, Carlsbad, CA) supplemented with 1 % fetal bovine serum (FBS; Invitrogen/ Gibco) to a 50 mM final concentration. These freshly prepared peptide solutions were incubated with HCECs, cultured as described above, for 12 or 24 h. In co-incubation experiments, 100 mM TUDCA was added to the cell cultures 12 h prior to the addition of Ab peptides. As negative controls, cells were separately incubated either in the absence of amyloid peptides or with TUDCA alone. In all cases, attached cells were either fixed for Hoechst staining and immunocytochemistry analysis, or processed for viability assays. For Western blot analysis, attached and floating cells were combined prior to the preparation of cytosolic and mitochondrial protein fractions and subsequent protein extraction.
Measurement of cell death. Cell viability was measured by trypan blue exclusion and by the lactate dehydrogenase (LDH) viability assay (Sigma) according to the manufacturers instructions. Apoptotic nuclei were detected by Hoechst labeling after cell fixation with 4 % formaldehyde in PBS, for 10 min at room temperature. Following incubation with Hoechst dye 33258 (Sigma) at 5 mg/ml in PBS for 5 min, and PBS washes, slides were mounted with PBS:glycerol (3:1, v/v) and fluorescence visualized with an Axioskop fluorescence microscope (Carl Zeiss GmbH, Hamburg, Germany). Fluorescent nuclei were scored and categorized according to the condensation and staining characteristics of chromatin. Normal nuclei showed non-condensed chromatin dispersed over the entire nucleus. Apoptotic nuclei were identified by condensed and fragmented chromatin contiguous to the nuclear membrane, as well as nuclear fragmentation and presence of apoptotic bodies. Three random microscopic fields per sample of approximately 250 nuclei were counted and mean values expressed as the percentage of apoptotic nuclei.
Immunocytochemistry. After 24 h of exposure to the respective amyloid peptides, both in the presence and absence of TUDCA, HCECs were either directly processed for mitochondria labeling in live cells or For cytochrome c immunostaining, after Ab challenge and fixation, HCECs were incubated for 1 h with PBS containing 0.3 % Triton X-100 (PBST) and 20 mg/ml bovine serum albumin (BSA). This was followed by 2 h incubation with monoclonal antibody anti-cytochrome c (BD Biosciences, Franklin Lakes, NJ; 1:200 in PBST containing 5 mg/ml BSA) and 1 h reaction with Alexa Fluor 488 conjugated anti-mouse secondary antibody (Invitrogen; 1:200 in PBST with 5 mg/ ml BSA). Slides were mounted with Dapi-containing Mounting Medium (Vectashield, Burlingame, CA) and images acquired in a Nikon Eclipse E-800 Deconvolution Microscope, using Image-Pro Plus software (Media Cybernetics, Silver Springs, MD) and Autodeblur (AutoQuant Imaging, Inc., Watervliet, NY) for deconvolution. Specificity of immune detection was assessed by omission of the primary antibody.
Bax translocation and cytochrome c release. Subcellular distribution of Bax and cytochrome c in amyloidchallenged HCECs was determined using mitochondrial and cytosolic protein extracts. Briefly, cells were collected by centrifugation at 600 g for 5 min at 48C. The pellets were washed once in ice-cold PBS and resuspended with 3 volumes of isolation buffer (20 mM HEPES/KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT) supplemented with Complete protease inhibitor cocktail tablets (Roche Diagnostics GmbH, Mannheim, Germany), in 250 mM sucrose. After chilling on ice for 15 min, cells were disrupted by 40 strokes of a glass homogenizer, and homogenates were centrifuged twice at 2500 g for 10 min at 48C to remove unbroken cells and nuclei. The supernatants were further centrifuged at 12 000 g for 30 min at 48C, and the pellets containing the mitochondrial fraction resuspended in isolation buffer and frozen at -808C. For cytosolic proteins, the 12 000 g supernatants were collected, filtered sequentially through 0.2 mm and 0.1 mm Ultrafree MC filters (Millipore, Bedford, MA) to remove other cellular organelles, and frozen at -808C. Protein concentrations of the subcellular fractions were determined using the Bio-Rad protein assay kit according to the manufacturers specifications. For Western blot detection of cytochrome c and Bax, typically 10 mg of mitochondrial and 50 mg of cytosolic proteins were separated on 15 % SDS-PAGE and transferred onto nitrocellulose membranes. After sequentially blocking with 15 % H 2 O 2 and 5 % non-fat milk (1 h, room temperature), membranes were separately incubated overnight at 48C with mouse monoclonal anti-Bax (Santa Cruz Biotechnology) and anti-cytochrome c (PharMingen, San Diego, CA) diluted 1:500, and 1:2000, respectively. Finally, immunoblots were incubated with HRP-conjugated secondary antibodies (Bio-Rad Laboratories; 1:5000, 3 h, room temperature) and processed for chemiluminescence detection using the SuperSignal Chemiluminescent Substrate (Thermo Scientific). Mitochondrial contamination of the cytosolic protein extracts was assessed with cytochrome c oxidase II (Cox II; Santa Cruz Biotechnology; 1:200). Cox II and b-actin (Sigma; 1:25 000) were used as loading controls for mitochondrial and cytosolic fractions, respectively.
Statistical analysis. Statistical analysis was performed using GraphPad InStat version 3.00 (Graph-Pad Software) for the analysis of variance and Bonferronis multiple comparison tests. Values of p<0.05 were considered significant.
Results
TUDCA does not affect Ab peptide aggregation and secondary structure. It has been postulated that Ab toxicity correlates with peptide aggregation propensity. Based on our previous findings demonstrating an inhibitory role of TUDCA on Ab neurotoxicity, we studied its effect on the aggregation/fibrillization properties of the Dutch variant comparing with wildtype Ab40 and Ab42. As indicated in Figure 1a , wildCell. Mol. Life Sci.
Vol. 66, 2009 Research Article type Ab40 remained mostly monomeric up to 48 h of incubation, with the appearance of only faint dimeric bands on Western blot analysis at this time point. In contrast, as expected, Ab42 showed high tendency to aggregate. Dimers and even faint tetrameric species were observed immediately after solubilization, whereas high molecular mass aggregates were readily visible at 24 h and accentuated at 48 h. AbE22Q showed an intermediate behavior with the formation of SDS-resistant oligomeric assemblies clearly noticeable at 48 h incubation but of lower molecular masses than those of Ab42. Notably, in all cases, co-incubation with TUDCA resulted in no significant changes in the aggregation properties of the different peptides. The effect of TUDCA on the fibrillogenic propensity of the peptides was assessed by Thioflavin T binding. Co-incubation with TUDCA did not modify the inherent properties of each peptide (Fig. 1b) . In fact, Ab42 continued to express the highest fluorescence values, while Ab40 levels remained negligible even at 48 h. AbE22Q showed an intermediate behavior, in agreement with the aggregation pattern shown in Figure 1a . Secondary structure analysis by CD spectroscopy illustrated both the different structural characteristics of the peptides and the lack of effect of TUDCA (Fig. 1c) . The initial Ab40 structure showed a minimum at 198 nm, characteristic of unordered conformations. Within 48 h of incubation, the peptide acquired a b-sheet-rich structure showing the typical minimum at 218 nm in the CD scan. Ab42 showed a predominantly b-sheet conformation even immediately after solubilization. AbE22Q exhibited an intermediate structural configuration, in agreement with the data illustrated in Figure 1a and b, with a mixture of random and b-sheet components when freshly solubilized and an increase in the b-sheet component at 48 h. However, AbE22Q did not achieve the predominant b-sheet conformation of the Ab42 in the time frame of the experiments. Corroborating the Western blot and Thioflavin T data, co-incubation with TUDCA did not induce conformational changes in the secondary structures of any of the Ab peptides studied.
TUDCA inhibits AbE22Q-induced apoptosis in brain microvascular endothelial cells. Morphologic evalua- tion of apoptosis induced by Ab peptides in HCEC was performed by fluorescence microscopy following Hoechst staining (Fig. 2a) . The results showed that nuclear fragmentation was differentially triggered by Ab peptides, starting at 12 h of treatment, with a maximum at 24 h, under the conditions tested. Interestingly, the AbE22Q variant was very aggressive in HCECs, increasing apoptosis by almost threefold compared to controls (p<0.001), in contrast to wildtype Ab40 and Ab42, which had almost no effect (Fig. 2b) . Consistent with its vasculotropic properties, AbE22Q did not significantly increase cell death in primary rat cortical neurons (unpublished observations). TUDCA was highly effective at modulating AbE22Q-induced toxicity, significantly inhibiting peptide-induced nuclear fragmentation to levels comparable to controls (p<0.05). Trypan blue dye exclusion and LDH levels (data not shown) were in accordance with the morphological results. Detailed characterization of the structural assemblies of AbE22Q indicated that the induction of apoptosis correlated with the presence of peptide oligomers of low molecular mass and intermediate Thioflavinbinding capacity (Fig. 1) . Notably, pre-treatment with TUDCA did not induce significant changes either in the peptide structure or in the aggregation/ fibrillization propensity.
TUDCA prevents AbE22Q-induced mitochondrial Bax translocation and cytochrome c release. To further investigate the cell death pathways differentially triggered by Ab peptides in HCECs, we sought to determine the specific involvement of the mitochondrial pathway of apoptosis. Our results showed that the AbE22Q mutant was very effective at triggering cytochrome c translocation from mitochondria to the cytosol when compared to Ab40 and Ab42 (Fig. 3) , which exhibited almost negligible effects. This is consistent with the lack of ability of the wild-type peptides to induce major apoptotic changes in HCECs. Data on Bax translocation from the cytosol to mitochondria, assessed by Western blot, were in agreement with cytochrome c changes (Fig. 3) . The role of TUDCA in preventing AbE22Q-induced, mitochondria-dependent cell death was assessed by immunofluorescence microscopy. We confirmed that incubation of HCECs with the AbE22Q mutant resulted in cytochrome c release from mitochondria as illustrated by strong cytoplasmic staining, which was mostly abolished by TUDCA (Fig. 4) . In addition, our results demonstrated that TUDCA significantly reduced co-localization of Bax with mitochondrial markers after incubation of HCECs with AbE22Q (Fig. 5a ). In fact, TUDCA reduced mitochondrial colocalization of Bax to control values ( Fig. 5b; p<0.05 ).
Discussion
Extensive CAA is the neuropathological hallmark of familial AD cases linked to intra-Ab mutations. These Ab genetic variants show potent vasculotropic properties and result in a predominant deposition of Ab Research Article peptides ending at position 40 [38 -40] . These are also the species that target the vasculature in sporadic AD, in contrast with the primary association of Ab42 with the parenchymal deposits [41, 42] . Aggregation/fibrillization of Ab plays a critical role in neurodegeneration. It is now considered that the transition from soluble monomeric species circulating under normal conditions to the oligomeric, protofibrillar and end-point fibrillar assemblies contribute significantly to disease pathogenesis. In particular, intermediate oligomeric and protofibrillar forms seem to display the most potent effects in neuronal cells, inducing synaptic disruption and neurotoxicity (reviewed in [43, 44] ). In contrast, the abundance of mature amyloid plaques correlates poorly with AD severity [45, 46] . Mutants with accelerated formation of intermediate species and increased stability of these structures, such as the Arctic (E22G) variant, elicit an earlier and stronger effect on neuronal cells compared with wild-type peptides [21, 47] . In contrast, the effect of Ab genetic variants on cerebral vessel wall cells, specifically on endothelial cells, has not been so well characterized. The E22Q peptide has been shown to selectively exert deleterious effects on these cells, significantly increasing apoptotic responses in comparison to the wild-type Ab40 [9, 19] . Nevertheless, the nature of the amyloid assemblies inducing toxicity remains uncertain. In the present study, we characterized in detail the conformational properties of the E22Q peptide triggering apoptotic responses in HCECs and demonstrated its intermediate fibrillogenic/aggregation properties and content of b-sheet conformation compared with wild-type Ab40 and Ab42. At one extreme, Ab40 exhibited a virtual lack of oligomerization; at the other, Ab42 showed high molecular mass assemblies with strong fibrillar components. The absence of apoptosis resulting from endothelial challenge with both wild-type peptides suggests that the intermediate conformation of the E22Q oligomeric assemblies accounts for the potent, specific apoptotic effect of this genetic variant. The limited high-order oligomerization/fibrillization observed in AbE22Q correlates well with the findings from nuclear magnetic resonance spectroscopy and molecular dynamics simulation studies, which highlight the effect of the mutation in fibril stabilization [ 48, 49] . These studies indicate that the wild-type Ab peptide, although mostly unstructured in solution, bears some regions exhibiting structural order and protease resistance. A fragment stretching from amino acids 21 through 30 adopts a stable bend structure which appears to nucleate monomer folding [50] . The turn is stabilized by hydrophobic interactions between Val24 and Lys28 and by long-range electrostatic interactions between Lys28 and either Glu22 or Asp23. The computational studies predicted that the E22Q mutation would translate into destabilization of the turn and enhanced oligomerization propensity [51, 52] , consistent with our findings. Also, a contributing factor to the nucleation propensity of the Dutch variant may be constituted by the depletion of the Glu22-Lys28 salt bridge as a consequence of the Glu-for-Gln substitution [52] . The major form of apoptosis in mammalian cells proceeds through the mitochondrial pathway, which involves mitochondrial outer membrane permeabilization and modulation by the Bcl-2 family of proteins. While some members of this family, typically located in the mitochondrial membrane, are potent inhibitors of apoptosis, others, including Bax, are pro-apoptotic and predominantly cytosolic (reviewed in [53] ). Upon commitment to apoptosis, and after mitochondrial translocation, Bax undergoes conformational changes, oligomerizes and forms pores in the outer mitochondrial membrane, allowing the release of proteins, including apoptogenic cytochrome c, to the cytoplasm. These events facilitate downstream stages of the cell death cascades, leading to DNA fragmentation and formation of apoptotic bodies. Our data clearly demonstrate that AbE22Q is a strong inducer of the Bax pro-apoptotic mitochondrial pathway in HCEC and highlights its role in various downstream events. In fact, E22Q increased mitochondrial Bax and, consequently, cytosolic cytochrome c. As expected, both events were accompanied by downstream nuclear fragmentation. Although apoptosis indicators have not been investigated in HCHWA-D cases, it is noteworthy that studies in AD patients have demonstrated alterations in the expression of apoptosis-related genes, such as Bax [54, 55] , suggesting that this process also takes place in vivo.
TUDCA is an endogenous bile acid that modulates the apoptotic threshold by interfering with classical mitochondrial pathways of cell death [24] . It has been previously shown that TUDCA is neuroprotective in pharmacological and transgenic mouse models of Huntingtons disease [27, 56] , reduces lesion volumes in rat models of ischemic and hemorrhagic stroke [28, 57] , improves survival and function of nigral transplants in a rat model of Parkinsons disease [26] , and partially rescues from mitochondrial dysfunction a Parkinsons disease model in Caenorhabditis elegans [58] . Additionally, TUDCA modulates Ab-induced neuronal death by inhibiting the mitochondrial ma- Research Article chinery and enhancing survival signaling [30] , most likely through functional modulation of nuclear steroid receptors [32] . In particular, TUDCA was shown to mitigate primary neuron mitochondrial insufficiency and toxicity by inhibiting Bax translocation from cytosol to mitochondria [59] and subsequent downstream events ending in caspase activation, substrate cleavage and ultimately cell death. In this study, we show that TUDCA additionally protects brain microvascular endothelial cells from the apoptotic insult triggered by the potent vasculotropic E22Q peptide through suppression of Bax translocation, cytochrome c release and subsequent cell death. Notably, despite its potent antiapoptotic role, TUDCA pre-treatment did not significantly alter the aggregation properties, fibrillogenic capacity or secondary structure of the Ab peptides in our experimental in vitro paradigm. Future experiments should clarify whether TUDCA has any differential effect in the peptide fibrillization occurring in cell culture conditions. The present data highlight a dichotomy between aggregation/fibrillization patterns and apoptotic properties of Ab peptides in HCECs. Whether these observations downplay the role of high molecular mass structural assemblies in the induction of apoptosis, or simply indicate that TUDCA directly affects upstream pathways remains to be elucidated. It is conceivable that TUDCA may bind to the monomers/ small oligomers of the Ab peptides, affecting their capability to insert into lipid bilayers and form channels [60, 61] . Alternatively, as a cholesterolderived molecule, TUDCA may insert into cellular membranes [62, 63] , thus preventing the subsequent insertion of Ab. Certainly, further studies are needed to identify the exact targets of TUDCA; nevertheless, this work provides new perspectives for the modulation of amyloid-induced toxicity in CAA, presenting new targets for therapeutic interventions.
